SOBRsafe Inc. (NASDAQ: SOBR), a company specializing in next-generation alcohol detection technology, announced it has entered into definitive agreements for the immediate exercise of certain outstanding warrants. The transaction is expected to generate gross proceeds of approximately $3.1 million before fees and expenses, with the warrants exercised at a reduced price of $1.05 per share.
In connection with the exercise, SOBRsafe will issue new unregistered Series E and Series F warrants to purchase an aggregate of 4.7 million shares. The offering is anticipated to close on or about July 16, 2026. Net proceeds from the warrant exercise are designated for working capital and general corporate purposes, providing the company with additional liquidity to support its operations and growth initiatives.
H.C. Wainwright & Co. is serving as the exclusive placement agent for the transaction. The full press release detailing the offering is available at https://nnw.fm/jzJjF.
SOBRsafe’s technology is centered on transdermal alcohol detection, which identifies the presence of alcohol as emitted through a user’s skin in real time, without requiring breath, blood, or urine samples. The company’s backend data platform supports passive and dignified screening and monitoring solutions for behavioral health, family law, consumer markets, and licensing and integration applications. This funding may enable SOBRsafe to further develop its technology and expand its market reach, particularly as demand for non-invasive alcohol monitoring solutions grows in various sectors.
The capital infusion comes at a time when SOBRsafe is working to establish its presence in the behavioral health and family law markets, where reliable and user-friendly alcohol monitoring can play a critical role in treatment and compliance. By strengthening its balance sheet, the company is better positioned to invest in sales, marketing, and product development. For leaders in business and technology, SOBRsafe’s funding round signals continued investor interest in innovative health-tech solutions that address societal challenges such as alcohol misuse.
This development also highlights the use of warrant exercise agreements as a financing mechanism for public companies. By incentivizing warrant holders to exercise early at a reduced price, SOBRsafe secures immediate capital while potentially minimizing dilution compared to a traditional equity offering. The issuance of new warrants may also provide a path for future capital if those warrants are exercised.
SOBRsafe’s newsroom and additional updates are available at https://nnw.fm/SOBR. The company’s website at www.sobrsafe.com offers further details on its technology and markets.
